Friday, December 13, 2013

The Motley Fool: Mood-Altering News From the Pharma Space

As a longtime critic of Eli Lilly's (NYSE: LLY  ) R&D and clinical trial management, I can't say I was surprised to see the news that yet another phase 3 drug candidate failed -- this time it was edivoxetine in depression. That stings all the more with recent late-stage failures for drugs targeted at breast cancer, Alzheimer's, and schizophrenia. It also serves to highlight that the depression market is a challenging one, making the recent launch of a new and different depression drug from H. Lundbeck (NASDAQOTH: HLUYY  ) all the more interesting.

Click the link to read more:
Mood-Altering News From the Pharma Space

No comments: